Drugs / Salmeterol / fluticasone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01836016 | May 2013 → May 2015 | chronic obstructive pulmonary disease | Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmeterol / fluticasone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01836016 ↗ |
| Route | Inhaled | “Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations.” NCT01836016 ↗ |